Show simple item record

dc.contributor.authorGuzman, Carlos A
dc.contributor.authorBorsutzky, Stefan
dc.contributor.authorGriot-Wenk, Monika
dc.contributor.authorMetcalfe, Ian C
dc.contributor.authorPearman, Jon
dc.contributor.authorCollioud, Andre
dc.contributor.authorFavre, Didier
dc.contributor.authorDietrich, Guido
dc.date.accessioned2008-01-09T10:03:02Z
dc.date.available2008-01-09T10:03:02Z
dc.date.issued2006-05-01
dc.identifier.citationVaccines against typhoid fever. 2006, 24 (18):3804-11 Vaccineen
dc.identifier.issn0264-410X
dc.identifier.pmid16278037
dc.identifier.doi10.1016/j.vaccine.2005.07.111
dc.identifier.urihttp://hdl.handle.net/10033/15855
dc.description.abstractBecause of high infectivity and significant disease burden, typhoid fever constitutes a major global health problem. Implementation of adequate food handling practices and establishment of safe water supplies are the cornerstone for the development of an effective prevention program. However, vaccination against typhoid fever remains an essential tool for the effective management of this disease. Currently, there are two well tolerated and effective licensed vaccines. One is based on defined subunit virulence (Vi) polysaccharide antigen and can be administered either intramuscularly or subcutaneously and the other is based on the use of live attenuated bacteria for oral administration. The advantages and disadvantages of the various approaches taken in the development of a vaccine against typhoid fever are discussed, along with the potential for future vaccine candidates.
dc.language.isoenen
dc.subject.meshAntigens, Bacterialen
dc.subject.meshCross Reactionsen
dc.subject.meshHumansen
dc.subject.meshParatyphoid Feveren
dc.subject.meshPolysaccharides, Bacterialen
dc.subject.meshSalmonella paratyphi Aen
dc.subject.meshSalmonella typhien
dc.subject.meshTyphoid Feveren
dc.subject.meshTyphoid-Paratyphoid Vaccinesen
dc.subject.meshVaccines, Attenuateden
dc.subject.meshVaccines, Inactivateden
dc.subject.meshVaccines, Subuniten
dc.titleVaccines against typhoid fever.en
dc.typeArticleen
dc.contributor.departmentVaccine Research Group, Division of Microbiology, GBF-German Research Centre for Biotechnology, Mascheroder Weg 1, Braunschweig, Germany.en
dc.identifier.journalVaccineen
refterms.dateFOA2018-06-13T03:46:34Z
html.description.abstractBecause of high infectivity and significant disease burden, typhoid fever constitutes a major global health problem. Implementation of adequate food handling practices and establishment of safe water supplies are the cornerstone for the development of an effective prevention program. However, vaccination against typhoid fever remains an essential tool for the effective management of this disease. Currently, there are two well tolerated and effective licensed vaccines. One is based on defined subunit virulence (Vi) polysaccharide antigen and can be administered either intramuscularly or subcutaneously and the other is based on the use of live attenuated bacteria for oral administration. The advantages and disadvantages of the various approaches taken in the development of a vaccine against typhoid fever are discussed, along with the potential for future vaccine candidates.


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Guzman et al_final.pdf
Size:
277.1Kb
Format:
PDF
Description:
original document

This item appears in the following Collection(s)

Show simple item record